MariMed Inc. (MRMD)
| Market Cap | 29.94M -22.1% |
| Revenue (ttm) | 161.40M +2.2% |
| Net Income | -12.76M |
| EPS | -0.04 |
| Shares Out | 399.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 799,265 |
| Average Volume | 776,498 |
| Open | 0.0700 |
| Previous Close | 0.0750 |
| Day's Range | 0.06915 - 0.0767 |
| 52-Week Range | 0.0641 - 0.2300 |
| Beta | 1.34 |
| RSI | 46.02 |
| Earnings Date | May 13, 2026 |
About MariMed
MariMed Inc. engages in cultivation, production, and selling of branded cannabis products in the United States. The company sells cannabis flower, vapes, and concentrates under the Nature’s Heritage brand; and cannabis fruit chews that delivers better sleep, pain relief, stress relief, and others under Betty’s Eddies brand. It offers soft and chewy baked goods and a hot chocolate mix under Bubby’s Baked brand; cannabis-infused hydrating drink mix for discrete and on-the-go consumption under Vibations brand; and flower, vapes, and edibles under ... [Read more]
Full Company ProfileFinancial Performance
In 2025, MariMed's revenue was $159.83 million, an increase of 1.34% compared to the previous year's $157.71 million. Losses were -$14.48 million, 16.2% more than in 2024.
Financial StatementsNews
MariMed Earnings Call Transcript: Q1 2026
Q1 2026 saw 4% revenue growth year-over-year, stable gross margins, and improved profitability, driven by strong wholesale and retail performance in core markets. Expansion is planned in Massachusetts and Ohio, with immediate tax benefits expected from medical cannabis rescheduling.
MariMed Earnings release: Q1 2026
MariMed released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
MariMed Slides: Q1 2026
MariMed has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 14, 2026.
MariMed Quarterly report: Q1 2026
MariMed has published its Q1 2026 quarterly earnings report on May 14, 2026.
MariMed Reports First Quarter 2026 Earnings
NORWOOD, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQB: MRMD), a leading multi-state cannabis operator focused on improving lives every day, toda...
MariMed Proxy statement: Proxy filing
MariMed filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
MariMed Announces First Quarter 2026 Earnings Date
NORWOOD, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQB: MRMD), a leading cannabis consumer packaged goods company and retailer, announced today...
MariMed Earnings Call Transcript: Q4 2025
Revenue grew 7% to $160M in 2025, with strong wholesale gains and expanded brand reach via licensing. Margin discipline, positive cash flow, and a strengthened balance sheet position the company for further growth, despite ongoing price compression in mature markets.
MariMed Annual report: Q4 2025
MariMed has published its Q4 2025 annual report on March 12, 2026.
MariMed Earnings release: Q4 2025
MariMed released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.
MariMed Slides: Q4 2025
MariMed has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 12, 2026.
MariMed Reports Fourth Quarter and Full Year 2025 Earnings
NORWOOD, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, to...
MariMed Extends Series B Preferred Stock Obligation Through 2031, Strengthening Capital Structure
NORWOOD, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed” or “the Company”) (CSE: MRMD) (OTCQX: MRMD), a leading cannabis consumer packaged goods company and retailer, announced today...
MariMed Announces Fourth Quarter and Full Year 2025 Earnings Date
NORWOOD, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading cannabis consumer packaged goods company and retailer, announced today ...
Marimed’s Betty’s Eddies introductions ‘Berry in Love Betty’
Betty’s Eddies is expanding its lineup with a new limited-edition batch of strawberry chocolate chews in time for Valentine’s Day: Berry In Love Betty. Now available at MariMed’s (MRMD) Thrive…
Marimed launches hemp-derived THC products under Vibations brand
MariMed (MRMD) announced the launch of a hemp-derived THC version of its Vibations hydrating drink mix brand in Rhode Island. The launch represents an opportunity for the Company to expand…
Marimed commends Trump Administration for reclassifying cannabis to Schedule III
MariMed (MRMD) issued the following statement from CEO Jon Levine: “We commend President Trump and the Trump Administration for reclassifying cannabis as a Schedule III drug. This is the single…
MariMed Statement on Historic Rescheduling of Cannabis
NORWOOD, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator committed to improving lives every day, issued the followi...
Veterans Healing Journey Becomes Soundtrack of Thrive Dispensaries
Veteran and customer of Thrive Dispensary in Anna, IL writes song of appreciation for Thrive and to raise visibility for veteran's org FreedomSingsUSA.
Marimed’s Betty’s Eddies expands lineup of chews for the winter
Betty’s Eddies is expanding its lineup with a new limited-edition batch of cranberry orange chews for the winter: Bundle Up Betty’s. Betty’s Eddies is one of the top-selling and award-winning…
MariMed's Betty's Eddies™ Introduces New Limited-Edition Winter Seasonal Cranberry Orange Fruit Chew, Bundle Up Betty's
Bundle Up Betty's Uses Real Cranberry, Orange, and Warming Spices in Each Fruit Chew to Deliver Cozy Winter Wind-Downs Bundle Up Betty's Uses Real Cranberry, Orange, and Warming Spices in Each Fruit C...
MariMed Earnings Call Transcript: Q3 2025
Q3 saw sequential growth in wholesale and retail revenue, with strong brand performance in core markets and a shift toward wholesale driving margin stability. Expansion into hemp and new licensing deals support long-term growth, while cost discipline improved cash flow and EBITDA.
MariMed Quarterly report: Q3 2025
MariMed has published its Q3 2025 quarterly earnings report on November 6, 2025.
MariMed Earnings release: Q3 2025
MariMed released its Q3 2025 earnings on November 6, 2025, summarizing the period's financial results.
MariMed Reports Third Quarter 2025 Earnings
NORWOOD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, tod...